Showing results (91-100 of 4,635) with videos related to

Sort By:
Pageof 464
Anti-Cancer Drugs|October 31, 2017
A genome-wide comprehensive analysis of alterations in driver genes in non-small-cell lung cancerJun Yi, Xiang Wei, Xinqiang Li, et al.
Anti-Cancer Drugs|January 24, 2018
FoxM1 promotes epithelial-mesenchymal transition, invasion, and migration of tongue squamous cell carcinoma cells through a c-Met/AKT-dependent positive feedback loopHuiling Yang, Li Wen, Mingling Wen, et al.
Anti-Cancer Drugs|February 14, 2018
Treatment of pancreatic cancer with intravenous vitamin C: a case reportJeanne A Drisko, Oscar K Serrano, Lisa R Spruce, et al.
Anti-Cancer Drugs|January 31, 2018
Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell linesMichael I Koukourakis, Christos Kakouratos, Dimitra Kalamida, et al.
Anti-Cancer Drugs|November 1, 2006
Human and murine macrophages mediate activation of MEN 4901/T-0128: a new promising camptothecin analogue-polysaccharide conjugateMonica Binaschi, Massimo Parlani, Daniela Bellarosa, et al.
Anti-Cancer Drugs|November 1, 2006
Pannarin inhibits cell growth and induces cell death in human prostate carcinoma DU-145 cellsAlessandra Russo, Marisa Piovano, Laura Lombardo, et al.
Anti-Cancer Drugs|November 1, 2006
Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalpBernd Kasper, Dominique Lossignol, Thierry Gil, et al.
Anti-Cancer Drugs|August 31, 2006
Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysisDaniel R Budman, Richie Soong, Anthony Calabro, et al.
Anti-Cancer Drugs|August 31, 2006
Plasma protein binding of the investigational anticancer agent 2-methoxyestradiolNehal Lakhani, Alex Sparreboom, Jürgen Venitz, et al.
Anti-Cancer Drugs|August 31, 2006
Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three casesNagi S El-Saghir, Ihab I El-Hajj, Jawad A Makarem, et al.
Pageof 464